RxDoctor Payments Data

David Jameson, MD

Family Medicine · Stromsburg, NENPI 1083616502

Payments from drug & device makers

$1,336in general payments, 2019–2025

Across 86 payments — averaging $15.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$267
  • AstraZeneca$240
  • Boehringer Ingelheim$193
  • Lilly USA, LLC$178
  • Pfizer$99
  • Amgen$51
  • plus $308 from 12 others

What the payments were for

  • Food & beverage$1,330100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,336 in reported general payments places this provider in the 65th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$172,007
Medicare patients
351
Services billed
4,415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban143$82,160
XareltoRivaroxaban83$50,257
JardianceEmpagliflozin79$48,170
OzempicSemaglutide48$44,870
RybelsusSemaglutide40$30,740
TresibaInsulin Degludec25$26,753
MounjaroTirzepatide18$18,910
MyrbetriqMirabegron27$12,589
FarxigaDapagliflozin Propanediol12$7,145
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$6,111
Tresiba Flextouch U-100Insulin Degludec11$5,988
Celecoxib204$4,872
Levothyroxine Sodium504$4,191
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$4,079
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$4,061

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Tresiba$267$102,362113 claims
PfizerEliquis$99$82,160143 claims
Johnson & JohnsonXarelto$28$50,25783 claims
Boehringer IngelheimJardiance$193$48,17079 claims
Lilly USA, LLCMounjaro, Insulin Lispro, Humalog$178$22,43956 claims
AstraZenecaFarxiga, Symbicort$240$10,24225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Stromsburg

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →